ASLAN Pharmaceuticals (ASLN)
(Real Time Quote from BATS)
$0.47 USD
+0.01 (2.82%)
Updated May 2, 2024 03:08 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
ASLAN Pharmaceuticals Ltd. [ASLN]
Reports for Purchase
Showing records 41 - 60 ( 99 total )
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Phase 2b Atopic Dermatitis Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Strategic Collaboration Inked for Upcoming Clinical Studies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
3Q21 Financial Results; Biomarker Collaboration Effected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Positive Phase 1 Top-Line Data in Atopic Dermatitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Data Imminent; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Secured Loan Facility Established to Advance ASLAN003; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
2020 Financial Results Reported; ASLAN004 Clinical Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Positive ASLAN004 Dermatitis Data; Financing Complete; Raising PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN003 Appears Least Hepatotoxic Among DHODH Inhibitors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Atopic Dermatitis Trial Opens Expansion Cohort; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Atopic Dermatitis Data Readout Nears; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Enrollment Starts for Third Cohort in Atopic Dermatitis Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Advancing ASLAN003 in Autoimmune Diseases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Atopic Dermatitis Study Advancing; More Clinical Sites Added; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results; Patient Recruitment to Resume Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
ASLAN004 Recruitment Paused; Interruption Transient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y